loading page

“The Efficacy and Safety of Aripiprazole and Paliperidone 1 and 3-Month Long-Acting Preparations During The Maintenance of Schizophrenia in Clinical Practice”
  • +3
  • Gokce Saridogan,
  • Neset Nesetoglu,
  • Sema Ketenci,
  • Nazife Acet,
  • Duri Sehvar Unal,
  • Mehmet Zafer Goren
Gokce Saridogan
Istanbul Erenkoy Mental and Nervous Diseases Training and Research Hospital

Corresponding Author:drgokcesaridogan@gmail.com

Author Profile
Neset Nesetoglu
Istanbul University
Author Profile
Sema Ketenci
Atlas University
Author Profile
Nazife Acet
Istanbul Medeniyet University
Author Profile
Duri Sehvar Unal
Istanbul University
Author Profile
Mehmet Zafer Goren
Marmara University School of Medicine
Author Profile


Aim: To our knowledge; this is the first study that compared the efficacy and safety of aripiprazole 1-month and paliperidone 1-month and paliperidone 3-month long-acting forms preparations as well as plasma drug levels during the maintenance treatment of schizophrenia in the real world. Method: In our study, subjects were evaluated every month for four months with relevant psychiatric measures and plasma drug levels. Follow-up days were determined as days 0, 30, 60, and 90. Plasma drug levels of the treatments were analyzed by using LC/MS-MS. Results: No superiority was observed between the groups regarding PANSS positive and general psychopathology (p>0.05). It was observed that PANSS negative and total scores were statistically lower in the aripiprazole once-monthly group than in the paliperidone 3-month preparations (p<0.05). We observed that Quality of Life Scale interpersonal relations scores, the aripiprazole 1-month group exhibited higher scores than both of the paliperidone groups. Aripiprazole 1-month group scored higher than the paliperidone 1-month group in the intrapsychic foundations subscale (p<0.05). No significant difference was observed between extrapyramidal adverse effect, akathisia, and insight levels among the three groups (p>0.05). Aripiprazole 1- month group scored significantly lower than both paliperidone groups in the Arizona Sexual Experiences Scale (p<0.001). Aripiprazole metabolite was negatively correlated with depressive symptoms in the Calgary Depression Assessment Scale in Schizophrenia (p<0.05) and the Barnes Akathisia Rating Scale (p<0.05). Conclusion: Aripiprazole once-monthly showed superiority in efficacy aspects to PP3M but not PP1M and similar safety with both paliperidone formulations.